|
1
|
La Joie R, Ayakta N, Seeley WW, Borys E, Boxer AL, DeCarli C, Doré V, Grinberg LT, Huang E, Hwang JH, Ikonomovic MD, Jack C, Jagust WJ, Jin LW, Klunk WE, Kofler J, Lesman-Segev OH, Lockhart SN, Lowe VJ, Masters CL, Mathis CA, McLean CL, Miller BL, Mungas D, O'Neil JP, Olichney JM, Parisi JE, Petersen RC, Rosen HJ, Rowe CC, Spina S, Vemuri P, Villemagne VL, Murray ME, Rabinovici GD. Multisite study of the relationships between antemortem [ 11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. Alzheimers Dement 2019; 15:205-216. [PMID: 30347188 PMCID: PMC6368897 DOI: 10.1016/j.jalz.2018.09.001] [Citation(s) in RCA: 139] [Impact Index Per Article: 27.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2018] [Revised: 07/08/2018] [Accepted: 09/03/2018] [Indexed: 10/28/2022]
Abstract
INTRODUCTION We sought to establish the relationships between standard postmortem measures of AD neuropathology and antemortem [11C]PIB-positron emission tomography ([11C]PIB-PET) analyzed with the Centiloid (CL) method, a standardized scale for Aβ-PET quantification. METHODS Four centers contributed 179 participants encompassing a broad range of clinical diagnoses, PET data, and autopsy findings. RESULTS CL values increased with each CERAD neuritic plaque score increment (median -3 CL for no plaques and 92 CL for frequent plaques) and nonlinearly with Thal Aβ phases (increases were detected starting at phase 2) with overlap between scores/phases. PET-pathology associations were comparable across sites and unchanged when restricting the analyses to the 56 patients who died within 2 years of PET. A threshold of 12.2 CL detected CERAD moderate-to-frequent neuritic plaques (area under the curve = 0.910, sensitivity = 89.2%, specificity = 86.4%), whereas 24.4 CL identified intermediate-to-high AD neuropathological changes (area under the curve = 0.894, sensitivity = 84.1%, specificity = 87.9%). DISCUSSION Our study demonstrated the robustness of a multisite Centiloid [11C]PIB-PET study and established a range of pathology-based CL thresholds.
Collapse
Affiliation(s)
- Renaud La Joie
- Memory & Aging Center, Department of Neurology, University of California, San Francisco, CA, USA.
| | - Nagehan Ayakta
- Memory & Aging Center, Department of Neurology, University of California, San Francisco, CA, USA; Helen Wills Neuroscience Institute, University of California Berkeley, CA, USA
| | - William W Seeley
- Memory & Aging Center, Department of Neurology, University of California, San Francisco, CA, USA
| | - Ewa Borys
- Department of Pathology, Stritch School of Medicine, Loyola University, Maywood, IL, USA
| | - Adam L Boxer
- Memory & Aging Center, Department of Neurology, University of California, San Francisco, CA, USA
| | - Charles DeCarli
- Department of Neurology, University of California, Davis, CA, USA
| | - Vincent Doré
- Department of Molecular Imaging & Therapy, Centre for PET, Austin Health, Heidelberg, Victoria, Australia
| | - Lea T Grinberg
- Memory & Aging Center, Department of Neurology, University of California, San Francisco, CA, USA
| | - Eric Huang
- Memory & Aging Center, Department of Neurology, University of California, San Francisco, CA, USA
| | - Ji-Hye Hwang
- Memory & Aging Center, Department of Neurology, University of California, San Francisco, CA, USA
| | - Milos D Ikonomovic
- Department of Neurology, University of Pittsburgh, PA, USA; Department of Psychiatry, University of Pittsburgh, PA, USA
| | - Clifford Jack
- Department of Radiology, Mayo Clinic, Rochester, MN, USA
| | - William J Jagust
- Helen Wills Neuroscience Institute, University of California Berkeley, CA, USA
| | - Lee-Way Jin
- Alzheimer's Disease Center, Department of Pathology, University of California Davis, CA, USA
| | - William E Klunk
- Department of Neurology, University of Pittsburgh, PA, USA; Department of Psychiatry, University of Pittsburgh, PA, USA; Alzheimer's Disease Research Center, University of Pittsburgh, PA, USA
| | - Julia Kofler
- Department of Pathology, University of Pittsburgh, Pennsylvania, USA
| | - Orit H Lesman-Segev
- Memory & Aging Center, Department of Neurology, University of California, San Francisco, CA, USA
| | - Samuel N Lockhart
- Helen Wills Neuroscience Institute, University of California Berkeley, CA, USA; Department of Internal Medicine, Division of Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - Val J Lowe
- Department of Nuclear Medicine, Mayo Clinic, Rochester, MN, USA
| | - Colin L Masters
- The Florey Institute, The University of Melbourne, Melbourne, Victoria, Australia
| | | | - Catriona L McLean
- Department of Anatomical Pathology, Alfred Hospital, Melbourne, Australia
| | - Bruce L Miller
- Memory & Aging Center, Department of Neurology, University of California, San Francisco, CA, USA
| | - Daniel Mungas
- Department of Neurology, University of California, Davis, CA, USA
| | - James P O'Neil
- Helen Wills Neuroscience Institute, University of California Berkeley, CA, USA; Biomedical Isotope Facility, MBIB Division, Lawrence Berkeley National Laboratory, CA, USA
| | - John M Olichney
- Department of Neurology, University of California, Davis, CA, USA
| | - Joseph E Parisi
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA; Department of Neurology, Mayo Clinic, Rochester, MN, USA
| | | | - Howard J Rosen
- Memory & Aging Center, Department of Neurology, University of California, San Francisco, CA, USA
| | - Christopher C Rowe
- Department of Molecular Imaging & Therapy, Centre for PET, Austin Health, Heidelberg, Victoria, Australia
| | - Salvatore Spina
- Memory & Aging Center, Department of Neurology, University of California, San Francisco, CA, USA
| | | | - Victor L Villemagne
- Department of Molecular Imaging & Therapy, Centre for PET, Austin Health, Heidelberg, Victoria, Australia; The Florey Institute, The University of Melbourne, Melbourne, Victoria, Australia
| | | | - Gil D Rabinovici
- Memory & Aging Center, Department of Neurology, University of California, San Francisco, CA, USA; Helen Wills Neuroscience Institute, University of California Berkeley, CA, USA
| |
Collapse
|
|
2
|
Merry TL, Tran M, Dodd GT, Mangiafico SP, Wiede F, Kaur S, McLean CL, Andrikopoulos S, Tiganis T. Hepatocyte glutathione peroxidase-1 deficiency improves hepatic glucose metabolism and decreases steatohepatitis in mice. Diabetologia 2016; 59:2632-2644. [PMID: 27628106 DOI: 10.1007/s00125-016-4084-3] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/26/2016] [Accepted: 08/05/2016] [Indexed: 12/11/2022]
Abstract
AIMS/HYPOTHESIS In obesity oxidative stress is thought to contribute to the development of insulin resistance, non-alcoholic fatty liver disease and the progression to non-alcoholic steatohepatitis. Our aim was to examine the precise contributions of hepatocyte-derived H2O2 to liver pathophysiology. METHODS Glutathione peroxidase (GPX) 1 is an antioxidant enzyme that is abundant in the liver and converts H2O2 to water. We generated Gpx1 lox/lox mice to conditionally delete Gpx1 in hepatocytes (Alb-Cre;Gpx1 lox/lox) and characterised mice fed chow, high-fat or choline-deficient amino-acid-defined (CDAA) diets. RESULTS Chow-fed Alb-Cre;Gpx1 lox/lox mice did not exhibit any alterations in body composition or energy expenditure, but had improved insulin sensitivity and reduced fasting blood glucose. This was accompanied by decreased gluconeogenic and increased glycolytic gene expression as well as increased hepatic glycogen. Hepatic insulin receptor Y1163/Y1163 phosphorylation and Akt Ser-473 phosphorylation were increased in fasted chow-fed Alb-Cre;Gpx1 lox/lox mice, associated with increased H2O2 production and insulin signalling in isolated hepatocytes. The enhanced insulin signalling was accompanied by the increased oxidation of hepatic protein tyrosine phosphatases previously implicated in the attenuation of insulin signalling. High-fat-fed Alb-Cre;Gpx1 lox/lox mice did not exhibit alterations in weight gain or hepatosteatosis, but exhibited decreased hepatic inflammation, decreased gluconeogenic gene expression and increased insulin signalling in the liver. Alb-Cre;Gpx1 lox/lox mice fed a CDAA diet that promotes non-alcoholic steatohepatitis exhibited decreased hepatic lymphocytic infiltrates, inflammation and liver fibrosis. CONCLUSIONS/INTERPRETATION Increased hepatocyte-derived H2O2 enhances hepatic insulin signalling, improves glucose control and protects mice from the development of non-alcoholic steatohepatitis.
Collapse
Affiliation(s)
- Troy L Merry
- Metabolic Disease and Obesity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, 3800, Australia
- Faculty of Medical and Health Sciences, The University of Auckland, Aukland, New Zealand
| | - Melanie Tran
- Metabolic Disease and Obesity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, 3800, Australia
| | - Garron T Dodd
- Metabolic Disease and Obesity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, 3800, Australia
| | - Salvatore P Mangiafico
- Department of Medicine (Austin Hospital), The University of Melbourne, Melbourne, VIC, Australia
| | - Florian Wiede
- Metabolic Disease and Obesity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, 3800, Australia
| | - Supreet Kaur
- Metabolic Disease and Obesity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, 3800, Australia
| | - Catriona L McLean
- Department of Anatomical Pathology, Alfred Hospital, Prahran, VIC, Australia
| | - Sofianos Andrikopoulos
- Department of Medicine (Austin Hospital), The University of Melbourne, Melbourne, VIC, Australia
| | - Tony Tiganis
- Metabolic Disease and Obesity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, 3800, Australia.
| |
Collapse
|
|
3
|
Merry TL, Tran M, Dodd GT, Mangiafico SP, Wiede F, Kaur S, McLean CL, Andrikopoulos S, Tiganis T. Erratum to: Hepatocyte glutathione peroxidase-1 deficiency improves hepatic glucose metabolism and decreases steatohepatitis in mice. Diabetologia 2016; 59:2729. [PMID: 27743136 DOI: 10.1007/s00125-016-4124-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Troy L Merry
- Metabolic Disease and Obesity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, 3800, Australia
- Faculty of Medical and Health Sciences, The University of Auckland, Aukland, New Zealand
| | - Melanie Tran
- Metabolic Disease and Obesity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, 3800, Australia
| | - Garron T Dodd
- Metabolic Disease and Obesity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, 3800, Australia
| | - Salvatore P Mangiafico
- Department of Medicine (Austin Hospital), The University of Melbourne, Melbourne, VIC, Australia
| | - Florian Wiede
- Metabolic Disease and Obesity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, 3800, Australia
| | - Supreet Kaur
- Metabolic Disease and Obesity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, 3800, Australia
| | - Catriona L McLean
- Department of Anatomical Pathology, Alfred Hospital, Prahran, VIC, Australia
| | - Sofianos Andrikopoulos
- Department of Medicine (Austin Hospital), The University of Melbourne, Melbourne, VIC, Australia
| | - Tony Tiganis
- Metabolic Disease and Obesity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, 3800, Australia.
| |
Collapse
|